Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 clinical development program assessing the safety and efficacy of MAX-001 a non-opioid, non-NSAID as an oral therapy for the treatment of acute and chronic pain

Next Previous
Trial Profile

A phase 1 clinical development program assessing the safety and efficacy of MAX-001 a non-opioid, non-NSAID as an oral therapy for the treatment of acute and chronic pain

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nefopam (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors MAXONA Pharmaceuticals

Most Recent Events

  • 18 Mar 2025 According to Maxona Pharmaceuticals media release, the company is looking forward to presenting and publishing the Study MAX-001-101 full data set later this year
  • 18 Mar 2025 Results presented in a Maxona Pharmaceuticals media release.
  • 26 Feb 2025 According to Maxona Pharmaceuticals media release, company completed the MAX-001 Phase 1 clinical program earlier this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top